Ketamine Hydrochloride is a small molecule commercialized by Seelos Therapeutics, with a leading Phase II program in Major Depressive Disorder. According to Globaldata, it is involved in 6 clinical trials, of which 1 was completed, 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Ketamine Hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ketamine Hydrochloride is expected to reach an annual total of $41 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ketamine Hydrochloride Overview
Ereska (intranasal ketamine, PMI-150, SLS-002) is under development for the treatment of suicidality in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). The drug candidate is administered through intranasal route. It acts by targeting glutamate ionotropic receptor AMPA type subunit (AMPA) and glutamate ionotropic receptor NMDA type subunit.
It was also under development for the treatment of postoperative pain and pain in cancer patients.
Seelos Therapeutics Overview
Seelos Therapeutics (Seelos) is a clinical-stage biopharmaceutical company that focuses on developing novel technologies and therapeutics for the treatment of central nervous system (CNS) and other rare disorders. Its lead programs include SLS-002, SLS-005, and pipeline products include SLS-004, SLS-008, SLS-007, SLS-010 and SLS-012. Seelos pipeline products find application in treating various multiple CNS disorders including parkinson’s disease, sanflippo syndrome, suicidality post-traumatic stress disorders, major depressive disorders and other diseases such as atopic dermatitis, asthma, and pediatric esophagitis. It operates along with its subsidiaries. Seelos is headquartered in New York, the US.
The operating loss of the company was US$70.9 million in FY2022, compared to an operating loss of US$63.9 million in FY2021. The net loss of the company was US$73.5 million in FY2022, compared to a net loss of US$66.1 million in FY2021.
For a complete picture of Ketamine Hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.